Additional considerations included the patient's history of undergoing RT for another BCC without any adverse effects recorded during the two-year follow-up period and the failure of molecular genetic testing to identify pathogenic variants in the PTCH1 or SUFU genes. This evidence concerns the gene PTCH1 and skin basal cell carcinoma.